Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. [electronic resource]
Producer: 20130812Description: 1629-40 p. digitalISSN:- 1949-2553
- Administration, Oral
- Animals
- Antineoplastic Agents -- administration & dosage
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Drug Design
- Female
- High-Throughput Screening Assays
- Humans
- Inhibitory Concentration 50
- Injections, Intravenous
- MCF-7 Cells
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Inbred NOD
- Mice, SCID
- Microfilament Proteins -- metabolism
- Molecular Structure
- Molecular Targeted Therapy
- NIH 3T3 Cells
- Naphthyridines -- administration & dosage
- Neoplasms -- drug therapy
- Phosphorylation
- Proteasome Endopeptidase Complex -- metabolism
- Protein Kinase Inhibitors -- administration & dosage
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- RNA Interference
- Small Molecule Libraries
- Structure-Activity Relationship
- Time Factors
- Transfection
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
- src Homology Domains
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.